Naotoshi Sugimoto

机构：Osaka International Cancer Institute · ORCID：0000-0003-1995-5002

发表论文 410 篇 · 总被引 15029 次 · h-index 54

代表论文

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 698)
• Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial (2024 · Nature Medicine · 被引 99)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 22)
• Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer (2025 · Journal of Clinical Oncology · 被引 15)
• Theobromine improves hyperactivity, inattention, and working memory via modulation of dopaminergic neural function in the frontal cortex of spontaneously hypertensive rats (2024 · Food & Function · 被引 10)
• Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan (2024 · Cancer Medicine · 被引 9)